This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease. Abecma’s review was delayed after the FDA ...

Firefighters, police officer who responded to 9/11 in World Trade Center do have an increased risk of multiple myeloma. There are some other well-defined occupational exposures. For instance ...

Billionaire hotelier Ong Beng Seng has been diagnosed with cancer. The 79-year-old has been undergoing chemotherapy for multiple myeloma, which is a type of blood cancer characterised by abnormal ...

Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into optimising anti-CD38 antibody-containing quadruplet regimens (quads) for ...

Singapore's property magnate Ong Beng Seng, embroiled in a corruption case linked to former transport minister S. Iswaran, is ...

SINGAPORE: Malaysian billionaire businessman Ong Beng Seng, who is best known to Singaporeans for having brought Formula 1 to ...

SINGAPORE: Property tycoon Ong Beng Seng, who is facing two charges related to former transport minister S Iswaran's case, ...

PROPERTY tycoon Ong Beng Seng, who faces two criminal charges in relation to dealings with former minister S Iswaran, is ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, ...